Gabrail, N.
18  results:
Search for persons X
?
1

A Phase 1 Dose-escalation and Expansion Study of CUE-101, G..:

Colevas, A.D. ; Chung, C.H. ; Adkins, D....
International Journal of Radiation Oncology*Biology*Physics.  118 (2024)  5 - p. e87 , 2024
 
?
2

The Keynote B36 (EF-36) Pilot Study of Tumor Treating Field..:

Chen, A.B. ; Kotecha, R. ; Chaney, M....
International Journal of Radiation Oncology*Biology*Physics.  118 (2024)  1 - p. e8 , 2024
 
?
4

P2.12-07 Phase II Trial of LP-300 + Pemetrexed/Carboplatin ..:

Treat, J. ; Abdulla, N. ; Bank, B....
Journal of Thoracic Oncology.  18 (2023)  11 - p. S365 , 2023
 
?
6

Oprozomib (OPZ) and Dexamethasone (DEX) in Patients (Pts) W..:

Prada, C.P. ; Shain, K.H. ; Voorhees, P....
Clinical Lymphoma Myeloma and Leukemia.  15 (2015)  - p. e273 , 2015
 
?
 
?
10

Abstract No. 147: A phase III, randomized, double-blind, pl..:

Gabrail, N. ; Sandler, E. ; Charu, V....
Journal of Vascular and Interventional Radiology.  21 (2010)  2 - p. S57-S58 , 2010
 
?
11

467 Updated efficacy and safety results for a randomized ph..:

Garon, E.B. ; Neidhart, J. ; Neidhart, J.D....
European Journal of Cancer Supplements.  8 (2010)  7 - p. 150 , 2010
 
?
 
?
15

APF530 versus ondansetron, each in a guideline-recommended ..:

Schnadig ID ; Agajanian R ; Dakhil C...
https://www.dovepress.com/apf530-versus-ondansetron-each-in-a-guideline-recommended-three-drug-r-peer-reviewed-article-CMAR.  , 2017
 
1-15